Cargando…
Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study
BACKGROUND: Antiretroviral therapy (ART) efficiently reduces the morbidities and mortalities caused by HIV-1 infection and prevents the HIV epidemic. However, virologic failure (VF) occurs in some patients receiving ART experience, especially increases in those patients with intermittent or persiste...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402888/ https://www.ncbi.nlm.nih.gov/pubmed/37546367 http://dx.doi.org/10.2147/IDR.S419610 |
_version_ | 1785084941430685696 |
---|---|
author | Lan, Yun Ling, Xuemei Deng, Xizi Lin, Yaqing Li, Junbin Li, Liya He, Ruiying Cai, Weiping Li, Feng Li, Linghua Hu, Fengyu |
author_facet | Lan, Yun Ling, Xuemei Deng, Xizi Lin, Yaqing Li, Junbin Li, Liya He, Ruiying Cai, Weiping Li, Feng Li, Linghua Hu, Fengyu |
author_sort | Lan, Yun |
collection | PubMed |
description | BACKGROUND: Antiretroviral therapy (ART) efficiently reduces the morbidities and mortalities caused by HIV-1 infection and prevents the HIV epidemic. However, virologic failure (VF) occurs in some patients receiving ART experience, especially increases in those patients with intermittent or persistent low-level viremia (LLV). The presence of drug resistance mutations (DRMs) in LLV was a strong predictor of subsequent VF. The data on drug resistance (DR) or DRMs for HIV-1 infections at low-level viral load (LLVL) are limited in China. OBJECTIVE: To monitor the prevalence of HIV-1 drug resistance and to evaluate the risk factors associated with drug resistance in LLVL HIV-1 infections during ART in Guangdong, China. METHODS: Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing. Then, the genotypic resistance test was performed and DR was analyzed by the Stanford HIVDB program. Finally, DR-associated factors were identified by logistic regression analysis. RESULTS: We found that CRF01_AE (53.57%) and CRF07_BC (25.07%) were the dominant HIV-1 genotypes in LLVL in Guangdong between 2011 and 2022 but that the percentage of CRF01_AE showed a trend of decrease over time. M46 (1.49%), M184 (30.91%), and K103 (21.46%) were the dominant PI-, NRTI-, and NNRTI-associated mutations, respectively. The total DR rate was 47.06%. Specifically, PI (3.71%) showed a significantly lower DR rate than NNRTI (40.74%) and NRTI (34.14%). Duration of ART, initial ART regimen, ethnicity, and WHO clinical stages were associated with DR. CONCLUSION: The drug resistance rate among the LLVL during ART in Guangdong, China is high. The risk factors associated with HIV drug resistance should be seriously considered for better control. |
format | Online Article Text |
id | pubmed-10402888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-104028882023-08-05 Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study Lan, Yun Ling, Xuemei Deng, Xizi Lin, Yaqing Li, Junbin Li, Liya He, Ruiying Cai, Weiping Li, Feng Li, Linghua Hu, Fengyu Infect Drug Resist Original Research BACKGROUND: Antiretroviral therapy (ART) efficiently reduces the morbidities and mortalities caused by HIV-1 infection and prevents the HIV epidemic. However, virologic failure (VF) occurs in some patients receiving ART experience, especially increases in those patients with intermittent or persistent low-level viremia (LLV). The presence of drug resistance mutations (DRMs) in LLV was a strong predictor of subsequent VF. The data on drug resistance (DR) or DRMs for HIV-1 infections at low-level viral load (LLVL) are limited in China. OBJECTIVE: To monitor the prevalence of HIV-1 drug resistance and to evaluate the risk factors associated with drug resistance in LLVL HIV-1 infections during ART in Guangdong, China. METHODS: Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing. Then, the genotypic resistance test was performed and DR was analyzed by the Stanford HIVDB program. Finally, DR-associated factors were identified by logistic regression analysis. RESULTS: We found that CRF01_AE (53.57%) and CRF07_BC (25.07%) were the dominant HIV-1 genotypes in LLVL in Guangdong between 2011 and 2022 but that the percentage of CRF01_AE showed a trend of decrease over time. M46 (1.49%), M184 (30.91%), and K103 (21.46%) were the dominant PI-, NRTI-, and NNRTI-associated mutations, respectively. The total DR rate was 47.06%. Specifically, PI (3.71%) showed a significantly lower DR rate than NNRTI (40.74%) and NRTI (34.14%). Duration of ART, initial ART regimen, ethnicity, and WHO clinical stages were associated with DR. CONCLUSION: The drug resistance rate among the LLVL during ART in Guangdong, China is high. The risk factors associated with HIV drug resistance should be seriously considered for better control. Dove 2023-07-31 /pmc/articles/PMC10402888/ /pubmed/37546367 http://dx.doi.org/10.2147/IDR.S419610 Text en © 2023 Lan et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lan, Yun Ling, Xuemei Deng, Xizi Lin, Yaqing Li, Junbin Li, Liya He, Ruiying Cai, Weiping Li, Feng Li, Linghua Hu, Fengyu Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study |
title | Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study |
title_full | Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study |
title_fullStr | Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study |
title_full_unstemmed | Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study |
title_short | Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study |
title_sort | drug resistance profile among hiv-1 infections experiencing art with low-level viral load in guangdong china during 2011–2022: a retrospective study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402888/ https://www.ncbi.nlm.nih.gov/pubmed/37546367 http://dx.doi.org/10.2147/IDR.S419610 |
work_keys_str_mv | AT lanyun drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy AT lingxuemei drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy AT dengxizi drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy AT linyaqing drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy AT lijunbin drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy AT liliya drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy AT heruiying drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy AT caiweiping drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy AT lifeng drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy AT lilinghua drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy AT hufengyu drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy |